Psychoactive fungi

Alberta Palliative Patient Successfully Undergoes First Legal Psychedelic-Assisted Therapy in Alberta, Initial Outcomes Exceed Expectations

Retrieved on: 
Wednesday, January 6, 2021

ATMAwas selected to provide the therapeutic services by Alberta's first palliative patient to receive a Section 56 exemption from Health Canada, Mr. Anthony (Tony) White.

Key Points: 
  • ATMAwas selected to provide the therapeutic services by Alberta's first palliative patient to receive a Section 56 exemption from Health Canada, Mr. Anthony (Tony) White.
  • The Section 56 exemption granted White to undergo therapy that includes the use of psilocybin, an active hallucinogenic found in "magic mushrooms".
  • The initial psychedelic-assisted treatment was conducted on Friday, Jan 1st, 2021 and preliminary outcomes have been extremely positive.
  • According to White, "I would say that 50% of the extreme anxiety and depression I have been feeling just disappeared immediately.

Minerco Inc The Magic Mushroom Company Signs LOI with Jamaican Firm Lazurus Holistic to Grow, Process and Extract Psilocybin and Cannabis for Export to Canada and Europe

Retrieved on: 
Monday, January 4, 2021

In addition, through the JV with Lazurus, Minerco will inherit multiple cannabis licenses to grow, process, extract cannabis as well as psilocybin.

Key Points: 
  • In addition, through the JV with Lazurus, Minerco will inherit multiple cannabis licenses to grow, process, extract cannabis as well as psilocybin.
  • Minerco plans to export its wholesale product to Europe and Canada, as well as create is own brand "DOTMINES."
  • Through this Joint Venture, the company plans to advance its operations into the Cannabis /CBD/Psilocybin white label market.
  • Lazurus Holisitic an expert in mycelium recently completed there first export of Psilocybin mushrooms to Mydecine Innovations Group Inc. in Canada.

Four Top Psychedelic Stock Picks for 2021

Retrieved on: 
Monday, January 4, 2021

With this information on psychedelic medicine in mind, here are four psychedelic stocks that could show huge returns to investors in 2021:

Key Points: 
  • With this information on psychedelic medicine in mind, here are four psychedelic stocks that could show huge returns to investors in 2021:
    MindMed (OTCQB: MMEDF) offers the broadest and most diversified pipeline of psychedelic drugs in clinical development and R&D.
  • Mycotopia Therapy specializes in evidence-based research by offering a study of an individual's psychotherapy using psychedelic medicines aided by data collection and algorithms developed with the help of psychedelic practitioners.
  • 20/20 Global will be seeking other business opportunities in the psychedelic space including psychedelic retreats and medicinal mushrooms.
  • Most of the other companies are testing the organic version of the psychedelic compound that occurs naturally in magic mushrooms.

Allied Moves to Become Leader in Psilocybin Space with Intent to Acquire of Pacific Sun Fungi

Retrieved on: 
Thursday, December 24, 2020

Pacific Sun is a British Columbia corporation that has been working on Research and Development activities in the psilocybin space for the past 10 years.

Key Points: 
  • Pacific Sun is a British Columbia corporation that has been working on Research and Development activities in the psilocybin space for the past 10 years.
  • Over the past two years, in parallel with psilocybin moving into the pharmaceutical research realm, Allied has continued to develop its pharmaceutical research infrastructure.
  • Allied was born out of the need to support veterans and first responders suffering from PTSD with targeted cannabinoid solutions.
  • On December 20th, 2020, Allied moves to acquire Pacific Sun Fungi by signing Letter of Intent to acquire.

Psyched Wellness Commences Pre-Clinical Trials of Amanita Muscaria

Retrieved on: 
Wednesday, December 23, 2020

Psyched Wellness Ltd. is a Canadian-based health supplements company dedicated to the distribution of mushroom-derived products and associated consumer packaged goods.

Key Points: 
  • Psyched Wellness Ltd. is a Canadian-based health supplements company dedicated to the distribution of mushroom-derived products and associated consumer packaged goods.
  • The Company's objective is to create premium mushroom-derived products that have the potential to become a leading North American brand in the emerging functional food category.
  • The Company is in the process of developing a line of Amanita muscaria-derived water-based extracts, teas and capsules designed to help with three health objectives: promote stress relief, relaxation and assist with restful sleeping.
  • This news release includes data that has been obtained from third party sources, including the findings from the Toxicology Assessment.

Minerco Inc. the Magic Mushroom Company Gains Acceptance in Psychedelic Invest Index of 20 Companies Total Volume 1.17b Volume

Retrieved on: 
Monday, December 21, 2020

New York, New York--(Newsfile Corp. - December 21, 2020) - Minerco Inc. (OTC Pink: MINE) gains appointment to the Psychedelic Invest Index made up of 20 companies listed.

Key Points: 
  • New York, New York--(Newsfile Corp. - December 21, 2020) - Minerco Inc. (OTC Pink: MINE) gains appointment to the Psychedelic Invest Index made up of 20 companies listed.
  • The 30 day average volume being $577.35m gives MINERCO greater exposure to the investment community.
  • This is a considerable milestone that within 12 months of MINE's new ownership it joins an elite class of 20 companies.
  • OTC: MINE emerging as the world's first publicly traded company focused on the research, production and distribution of psilocybin mushroom.

PharmaTher Signs LOI to Sell Psilocybin Program to Revive Therapeutics

Retrieved on: 
Monday, December 21, 2020

PharmaTher is focusing on its lead clinical studies with ketamine for U.S. Food and Drug Administration (FDA) approvals in Parkinsons disease, depression and pain.

Key Points: 
  • PharmaTher is focusing on its lead clinical studies with ketamine for U.S. Food and Drug Administration (FDA) approvals in Parkinsons disease, depression and pain.
  • We have built a diverse intellectual property portfolio of novel uses and FDA-approved drug combinations of psilocybin for neurological disorders for a strategic partner such as Revive, which has committed to developing novel psilocybin formulations, to unlock value of the psilocybin program for the long-term, said Fabio Chianelli, CEO of PharmaTher.
  • 63/011,493 Relates to pharmaceutical compositions comprising psilocybin and their use for the treatment of neurological brain injuries and migraines.
  • With its recent acquisition of Psilocin Pharma Corp., Revive is advancing the development of Psilocybin-based therapeutics in various diseases and disorders.

Push for Alternative Therapies Prods Researchers Towards Psilocybin

Retrieved on: 
Tuesday, December 15, 2020

According to the study, this provides an understanding of why psilocybin is showing considerable promise as a therapeutic intervention for neuropsychiatric disorders including depression, anxiety, and addiction.

Key Points: 
  • According to the study, this provides an understanding of why psilocybin is showing considerable promise as a therapeutic intervention for neuropsychiatric disorders including depression, anxiety, and addiction.
  • 'We are pleased to announce the completion of our first commercial harvest of natural psilocybin mushrooms,' said Joshua Bartch, CEO and Chairman of Mydecine.
  • Once received by the Company's facility in Canada, the psilocybin mushrooms will be extracted, purified, and turned into a cGMP final product for controlled therapeutic purposes.
  • Vic Neufeld, Executive Chairman of Havn Life stated: "We are tremendously excited about the potential to accelerate drug discovery and patient access to psilocybin based compounds.

Push for Alternative Therapies Prods Researchers Towards Psilocybin

Retrieved on: 
Tuesday, December 15, 2020

According to the study, this provides an understanding of why psilocybin is showing considerable promise as a therapeutic intervention for neuropsychiatric disorders including depression, anxiety, and addiction.

Key Points: 
  • According to the study, this provides an understanding of why psilocybin is showing considerable promise as a therapeutic intervention for neuropsychiatric disorders including depression, anxiety, and addiction.
  • 'We are pleased to announce the completion of our first commercial harvest of natural psilocybin mushrooms,' said Joshua Bartch, CEO and Chairman of Mydecine.
  • Once received by the Company's facility in Canada, the psilocybin mushrooms will be extracted, purified, and turned into a cGMP final product for controlled therapeutic purposes.
  • Vic Neufeld, Executive Chairman of Havn Life stated: "We are tremendously excited about the potential to accelerate drug discovery and patient access to psilocybin based compounds.

Way2Grow (W2G) Biopharma Company Enters Cannabis Productivity and Announces Plans to Seek Health Canada Approval for Magic Mushroom (Psilocybin and Psilocin) Dealer and Research Licencing

Retrieved on: 
Tuesday, December 15, 2020

Way2Grow received approval for a single-story production facility designed to support tissue culture and micropropagation and to meet organic cannabis cultivation, processing and medical sales requirements.

Key Points: 
  • Way2Grow received approval for a single-story production facility designed to support tissue culture and micropropagation and to meet organic cannabis cultivation, processing and medical sales requirements.
  • W2Gs research plans include the investigation of cannabis and psilocybin mushrooms growth plans and examination of their efficacy on treating unmet mental health conditions such as PTSD, addiction dependency, and anxiety.
  • W2Gs cultivation relies on a small, closed room approach to growing consistent organic medical cannabis and soon, medical grade psilocybin mushroom (Psilocybe semilanceata) production.
  • Way2Grow is located in Osoyoos, British Columbia, and is regulated under the Cannabis Act and the Cannabis Regulations (Canada).